Exchange: NASDAQ·Updated 07:34 PM EDT

ACHV News

News
all
press releases
Achieve Life Sciences Appoints Benjamin Halladay As CFO
(RTTNews) - Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, said on Thursday that it has appointed Benjamin Halladay as chief financial officer with effect from October 5. He will succeed Mark Oki, who will step down as CFO on the same day...
Nasdaq News: Markets
Achieve Life Sciences Appoints Benjamin Halladay As CFO
(RTTNews) - Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, said on Thursday that it has appointed Benjamin Halladay as chief financial officer with effect from October 5. He will succeed Mark Oki, who will step down as CFO on the same day...
Nasdaq News: Markets
More News
FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned
FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with NDA resubmission planned in Q4 2026.read more...
Benzinga
Achieve Life Sciences Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
Achieve Life Sciences (ACHV) to Release Quarterly Earnings on Tuesday
Achieve Life Sciences (NASDAQ:ACHV) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-achieve-life-sciences-inc-stock...
MarketBeat
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Passes Above 200 Day Moving Average - Time to Sell?
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell...
MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of "Buy" by Brokerages
Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has been assigned an average recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports...
MarketBeat
ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?
Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter.
Stocktwits
Achieve Life Sciences' (ACHV) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday...
MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm...
MarketBeat
What is Zacks Research's Estimate for ACHV FY2026 Earnings?
Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Zacks Research dropped their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on...
MarketBeat

Advertisement|Remove ads.